Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Electronic medical records of patients with diagnoses of schizophrenia, Bipolar Disorder (BPD) or Major Depressive Disorder (MDD) treated with Seroquel® or Seroquel®XR during the calendar periods: 13 Feb - 31 Aug 2012 seen by GP \& psychiatrists in Germany \& 11 Jan-31 July 2012 seen by GPs in the UK
You may not be if
\- Patients with above mentioned diagnoses treated with Seroquel® or Seroquel® XR/quetiapine fumarate not having any medical encounters during the time periods: 13 Feb - 31 Aug 2012 in Germany \& 11 Jan-31 July 2012 by GPs in the UK
Clareo Health | EMR Data to Assess Monitoring of Patients Treated With Quetiapine
